Sign In
Buy TCRX
$0.97
-0.0080 (-0.82%)
At Close: Jun 03, 2026
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
09:25am, Wednesday, 06'th May 2026
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.26 per share a year ago.
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
07:00am, Wednesday, 06'th May 2026
Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2 ™ ) planned for the second quar
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
04:30pm, Monday, 27'th Apr 2026
WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
07:00am, Wednesday, 08'th Apr 2026
WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates
09:16am, Wednesday, 04'th Mar 2026
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.29 per share a year ago.
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
07:00am, Wednesday, 04'th Mar 2026
Presented positive updated data from the ALLOHA ™ Phase 1 heme trial at 67 th American Society of Hematology (ASH) Annual Meeting and Exposition Announced completion of enrollment in Cohort C of Pha
Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
07:00am, Wednesday, 25'th Feb 2026
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of “Hold” from Brokerages
01:56am, Thursday, 19'th Feb 2026
TScan Therapeutics, Inc. (NASDAQ: TCRX - Get Free Report) has received an average rating of "Hold" from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One eq
Treatment arm continues to demonstrate favorable relapse-free survival (HR=0. 50; p=0. 23) and overall survival (HR=0. 61; p=0. 52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-u
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
12:20pm, Thursday, 04'th Dec 2025
/PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
04:05pm, Wednesday, 03'rd Dec 2025
WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates
09:26am, Wednesday, 12'th Nov 2025
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.25 per share a year ago.
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
07:00am, Wednesday, 12'th Nov 2025
Reached agreement with FDA on pivotal study design for TSC-101 following productive end of Phase 1 meeting Data from ALLOHA ™ Phase 1 heme trial to be presented at the 67 th American Society of Hema
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
07:00am, Wednesday, 05'th Nov 2025
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell
